Cholecystokinin (CCK)
Cholecystokinin (CCK) is a gut-brain peptide existing in multiple bioactive forms (CCK-8, CCK-33, CCK-58) that signals through CCK-A (peripheral) and CCK-B (CNS) receptors. It mediates gallbladder contraction, pancreatic secretion, satiety, and anxiety/panic responses, with CCK-4 serving as a validated panic-induction model.
Cholecystokinin (CCK) is a peptide hormone and neuropeptide originally discovered in 1928 for its ability to contract the gallbladder (Greek: chole = bile, cysto = bladder, kinin = to move). CCK exists in multiple bioactive forms produced by post-translational processing of a 115-amino acid precursor, with CCK-8 (sulfated octapeptide), CCK-33, and CCK-58 being the most physiologically significant.
Overview
CCK is produced by I-cells in the duodenal and jejunal mucosa in response to intraluminal fat and protein, and by neurons throughout the central nervous system where it functions as a neurotransmitter. It is one of the most abundant neuropeptides in the brain, with particularly dense expression in the cerebral cortex, hippocampus, amygdala, and periaqueductal gray. The biological activity of all CCK forms resides in the C-terminal octapeptide sequence (CCK-8), and sulfation of the tyrosine residue at position 7 (from the C-terminus) is essential for full CCK-A receptor activity.
CCK-A receptors (also designated CCK₁) are predominantly expressed in the periphery — gallbladder, pancreas, vagal afferents, and some brainstem nuclei — mediating digestive and satiety functions. CCK-B receptors (CCK₂), identical to gastrin receptors, are widely distributed in the CNS and mediate anxiety, panic, memory, and nociceptive effects. This receptor distribution creates a clear functional dichotomy between CCK's peripheral digestive roles and its central neuropsychiatric actions.
Mechanism of Action
CCK signals through two G-protein-coupled receptors with distinct distributions and coupling:
- CCK-A (CCK₁) receptor: Couples to Gq → PLC → IP₃/DAG → Ca²⁺ release. High affinity for sulfated CCK-8 (1000-fold selectivity over unsulfated form). Mediates gallbladder contraction, pancreatic enzyme secretion, and vagal afferent satiety signaling. Located on gallbladder smooth muscle, pancreatic acinar cells, vagal afferents, and pyloric sphincter Dufresne et al. (2006).
- CCK-B (CCK₂) receptor: Also couples to Gq → PLC → Ca²⁺. Equal affinity for sulfated and unsulfated CCK and for gastrin. Widely expressed in brain (cortex, amygdala, hippocampus, nucleus accumbens) and on gastric ECL cells. Mediates anxiety/panic responses, memory modulation, and gastric acid secretion Noble et al. (1999).
- Vagal satiety pathway: CCK released from I-cells activates CCK-A receptors on vagal afferent terminals in the duodenal mucosa, transmitting satiety signals to the nucleus of the solitary tract (NTS) → hypothalamus. This is the primary acute meal-termination pathway Moran & Kinzig (2004).
- Opioid interaction: CCK-B receptor activation opposes opioid analgesia. Endogenous CCK release during sustained opioid exposure contributes to analgesic tolerance. CCK-B antagonists potentiate and prolong opioid analgesia Faris et al. (1983).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Analgesic Interactions with Opioids
CCK functions as an endogenous anti-opioid peptide. CCK-B receptor activation in the periaqueductal gray, rostral ventromedial medulla, and spinal cord opposes opioid-mediated analgesia Faris et al. (1983). Opioid administration upregulates CCK expression, and this CCK release contributes to the development of opioid tolerance and hyperalgesia. CCK-B receptor antagonists (proglumide, L-365,260) potentiate morphine analgesia, prevent tolerance development, and enhance the analgesic efficacy of endogenous opioids. This CCK-opioid interaction has therapeutic implications for pain management and the design of combination analgesic strategies.
Gallbladder Contraction and Pancreatic Secretion
CCK is the primary physiological stimulus for gallbladder contraction and pancreatic enzyme secretion. Postprandial CCK release triggers coordinated gallbladder contraction, sphincter of Oddi relaxation, and pancreatic acinar cell degranulation, delivering bile and digestive enzymes to the duodenum. Sincalide (CCK-8, Kinevac) is FDA-approved as a diagnostic agent for cholecystography and pancreatic function testing Liddle et al. (1985). CCK dysregulation is implicated in functional gallbladder disorder and chronic pancreatitis, and CCK-A receptor polymorphisms have been associated with gallstone disease susceptibility.
CCK-4 and Panic Disorder
CCK-4 (the C-terminal tetrapeptide Trp-Met-Asp-Phe-NH₂) is the most validated pharmacological model for panic attacks in humans. Intravenous CCK-4 administration (25–50 µg) reliably induces panic symptoms — palpitations, dyspnea, derealization, fear of dying — in panic disorder patients and healthy volunteers, with panic disorder patients showing heightened sensitivity Bradwejn et al. (1991). This effect is mediated by CCK-B receptors in the amygdala and brainstem. The CCK-4 challenge has been used extensively to study panic neurobiology, test anxiolytic efficacy, and investigate genetic vulnerability to anxiety disorders. CCK-B receptor antagonists (e.g., L-365,260, CI-988) have shown anxiolytic effects in preclinical models but have not achieved clinical success due to pharmacokinetic limitations.
Memory and Cognition
CCK modulates memory through CCK-B receptors in the hippocampus and amygdala. CCK enhances long-term potentiation (LTP) at hippocampal synapses and facilitates memory consolidation in fear conditioning and spatial learning paradigms. CCK-expressing interneurons in the hippocampus coordinate network oscillations critical for memory encoding. Dysregulation of CCK signaling has been implicated in cognitive decline associated with Alzheimer's disease, schizophrenia, and age-related memory impairment Bhatt et al. (2021).
Satiety and Appetite Regulation
CCK was the first gut hormone demonstrated to reduce food intake. Peripheral CCK-8 administration reduces meal size and duration in both animals and humans, acting through CCK-A receptors on vagal afferents Gibbs et al. (1973). However, CCK produces meal termination (satiation) rather than inter-meal satiety — compensatory increases in meal frequency prevent weight loss from chronic CCK administration. This mechanistic limitation distinguishes CCK from longer-acting satiety hormones like PYY and GLP-1. CCK interacts with leptin signaling, and combined CCK-leptin administration produces synergistic food intake reduction and sustained weight loss in animal models.
Safety Profile
CCK has a well-established safety profile from decades of clinical diagnostic use (sincalide/Kinevac) and experimental challenge studies:
- GI effects: Nausea, abdominal cramping, and urgency at pharmacological doses, consistent with gallbladder contraction and increased GI motility. These are transient and dose-dependent.
- Panic/anxiety: CCK-4 and CCK-8s reliably induce anxiety and panic symptoms through CCK-B receptor activation. This is an expected pharmacological effect used diagnostically but limits therapeutic applications of non-selective CCK agonists.
- Cardiovascular: Transient increases in heart rate and blood pressure during panic induction. No significant cardiovascular toxicity at diagnostic doses.
- Short half-life: Rapid enzymatic degradation (~2–3 minutes) limits the duration of adverse effects.
- Sincalide (CCK-8): FDA-approved for gallbladder and pancreatic function testing. Contraindicated in acute pancreatitis and intestinal obstruction.
- Chronic exposure: No evidence of tachyphylaxis to CCK's satiety effects in acute studies, but compensatory meal frequency increases prevent long-term weight loss with chronic CCK alone.
Pharmacokinetic Profile
Cholecystokinin (CCK) — Pharmacokinetic Curve
Intravenous (research, diagnostic)Quick Start
- Route
- Intravenous (research, diagnostic)
Molecular Structure
- Weight
- 1143.3 Da
- CAS
- 9011-97-6 (unsulfated CCK-8)
Research Protocols
intravenous Injection
Intravenous CCK-4 administration (25–50 µg) reliably induces panic symptoms — palpitations, dyspnea, derealization, fear of dying — in panic disorder patients and healthy volunteers, with panic disorder patients showing heightened sensitivity [Bradwejn et al.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Panic disorder patients and healthy volun | 25–50 µg | Per protocol | — |
Interactions
Peptide Interactions
CCK functions as an endogenous anti-opioid peptide. CCK-B receptor activation in the brainstem and spinal cord opposes mu-opioid receptor-mediated analgesia and promotes opioid tolerance. Elevated CCK levels reduce opioid efficacy, while CCK antagonists (proglumide) have been shown to enhance morphine analgesia. (Faris et al., 1983, Science; Noble et al., 1999, Prog Neurobiol)
What to Expect
What to Expect
Rapid onset expected; half-life of ~2–3 minutes (plasma) indicates fast-acting pharmacokinetics
Due to short half-life (~2–3 minutes (plasma)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
Caution
- Short half-life may require frequent dosing
Frequently Asked Questions
References (12)
- [10]D'Amato M et al — CCK system pharmacology: receptor-selective agonists and antagonists in GI and CNS disorders Pharmacol Rev (2023)
- [12]van Bloemendaal L et al — Gut hormone combination therapy: CCK, PYY, and GLP-1 interactions in human appetite regulation Obesity (2023)
- [2]Liddle RA, Goldfine ID, Rosen MS, et al Cholecystokinin bioactivity in human plasma J Clin Invest (1985)
- [3]Bradwejn J, Koszycki D, Shriqui C Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder Arch Gen Psychiatry (1991)
- [5]Moran TH, Kinzig KP Gastrointestinal satiety signals II. Cholecystokinin Am J Physiol Gastrointest Liver Physiol (2004)
- [6]Noble F, Wank SA, Crawley JN, et al International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors Pharmacol Rev (1999)
- [7]
- [11]Rehfeld JF — Cholecystokinin — from local gut hormone to ubiquitous messenger Front Endocrinol (2022)
- [1]Gibbs J, Young RC, Smith GP Cholecystokinin decreases food intake in rats J Comp Physiol Psychol (1973)
- [4]Faris PL, Komisaruk BR, Watkins LR, Mayer DJ Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia Science (1983)
- [8]Bhatt DK, Bhatt S, Bhatt M Role of CCK in memory and cognition: a review Neurosci Biobehav Rev (2021)
- [9]Bhatt DK et al — CCK in neuropsychiatric disorders: beyond anxiety to cognitive and motivational dysfunction Neurosci Biobehav Rev (2022)
Cerluten
Cerluten is a complex peptide bioregulator preparation derived from brain tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for research in cognitive aging, neurodegeneration, and cerebral function. Distinguished from cortagen (AEDP), which is a single tetrapeptide CNS bioregulator.
Chonluten
Chonluten is a short tripeptide bioregulator (Glu-Asp-Gly) that modulates gene expression related to inflammation and antioxidant activity, with primary research focus on lung tissue and secondary effects in the gastrointestinal tract.